Pericardial effusion is the most common cardiac finding in pulmonary TB (14-56% prevalence), but cardiac biomarker and advanced imaging evidence remains extremely limited.
14-56% pericardial effusionUp to 56% of pulmonary TB patients showed pericardial effusion on echocardiography, yet cardiac monitoring is rarely part of routine TB care
What the researchers found
Pericardial effusion prevalence: 14.1-55.9% on echocardiography. LV systolic impairment: 0-4.25%. Myocardial inflammation: 0.6-21.8% on PET-CT. Only 1 study assessed cardiac biomarkers (BNP, troponin, CK-MB). Elevated troponin found in 246/800 patients. No CTCA studies identified.
Why it matters
TB kills 1.3 million people annually and is associated with increased long-term cardiovascular mortality. Understanding how TB damages the heart — and using biomarkers like BNP for early detection — could help reduce this excess mortality through timely cardiac monitoring and intervention.
The numbers in context
Not specified — systematic review synthesizing available evidence.
How the study worked
Systematic review of databases for studies evaluating cardiac pathology in PTB patients. Included studies using echocardiography, cardiac MRI, PET-CT, CT coronary angiography, cardiac troponin, and B-type natriuretic peptides. Seven studies with 1,333 participants met inclusion criteria.
Who was studied
Patients with pulmonary tuberculosis across multiple studies
What this study cannot tell us
Only 7 studies met inclusion criteria — very limited evidence base. Heterogeneous study designs and populations. Only 1 study assessed cardiac biomarkers. No coronary artery disease imaging data. Most studies used echocardiography, which may miss subtle myocardial pathology.
How to read the evidence
Rated moderate: systematic review methodology is strong, but the underlying evidence base is extremely limited (only 7 studies, 1 biomarker study). The review's value lies in identifying the evidence gap.
When this study was published
Published in 2024. Highlights a major research gap at the intersection of infectious disease and cardiology.
The bigger picture
TB is often thought of purely as a lung disease, but this review reveals significant cardiac involvement. As TB care improves and patients survive longer, the long-term cardiovascular consequences become increasingly important — particularly in resource-limited settings where cardiac monitoring is limited.
Questions still open
- Should routine cardiac biomarker screening (BNP, troponin) be part of TB management?
- Does TB treatment reverse the cardiac damage identified on imaging?
- What mechanisms link pulmonary TB to pericardial and myocardial inflammation?
Common questions
Can tuberculosis damage your heart?
Should TB patients get heart tests?
Read the original research
Imaging and Circulating Biomarker-Defined Cardiac Pathology in Pulmonary Tuberculosis: A Systematic Review.
Global heart, 19(1), 84
Citation
Scopazzini, Marcello S; Hill, Katherine J; Majonga, Edith D; Zenner, Dominik; Ayles, Helen; Shah, Anoop S V. (2024). Imaging and Circulating Biomarker-Defined Cardiac Pathology in Pulmonary Tuberculosis: A Systematic Review.. Global heart, 19(1), 84. https://doi.org/10.5334/gh.1369